Paula D Ryan

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer
    Paula D Ryan
    Massachusetts General Hospital, LRH 308, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 13:16-24. 2008
  2. ncbi Adjuvant hormonal therapy in peri- and postmenopausal breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Oncologist 11:718-31. 2006
  3. ncbi The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Boston, MA 02114, USA
    Nat Clin Pract Oncol 2:596-7. 2005
  4. ncbi Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers
    Janie M Lee
    Department of Radiology, Institute for Technology Assessment, Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 254:793-800. 2010
  5. ncbi Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis
    Kathryn P Lowry
    Massachusetts General Hospital Institute for Technology Assessment, Boston, Massachusetts, USA
    Cancer 118:2021-30. 2012
  6. ncbi VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:7871-7. 2008
  7. ncbi Which individuals undergoing BRACAnalysis need BART testing?
    Kristen M Shannon
    Massachusetts General Hospital, Center for Cancer Risk Assessment, Boston, MA, USA
    Cancer Genet 204:416-22. 2011
  8. ncbi Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8340-7. 2005
  9. ncbi Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
  10. ncbi Professional challenges in cancer genetic testing: who is the patient?
    Gayun Chan-Smutko
    Massachusetts General Hospital Cancer Center Center for Cancer Risk Assessment, Boston, MA 02114, USA
    Oncologist 13:232-8. 2008

Collaborators

Detail Information

Publications22

  1. ncbi The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer
    Paula D Ryan
    Massachusetts General Hospital, LRH 308, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 13:16-24. 2008
    ..In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data...
  2. ncbi Adjuvant hormonal therapy in peri- and postmenopausal breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Cox 640, 100 Blossom Street, Boston, Massachusetts 02114, USA
    Oncologist 11:718-31. 2006
    ..Areas of active investigation include the mechanisms of resistance to endocrine therapy with tamoxifen and AIs and clinical strategies to overcome this resistance...
  3. ncbi The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer
    Paula D Ryan
    Massachusetts General Hospital, Boston, MA 02114, USA
    Nat Clin Pract Oncol 2:596-7. 2005
  4. ncbi Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers
    Janie M Lee
    Department of Radiology, Institute for Technology Assessment, Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 254:793-800. 2010
    ..c) RSNA, 2010 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.09091086/-/DC1...
  5. ncbi Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis
    Kathryn P Lowry
    Massachusetts General Hospital Institute for Technology Assessment, Boston, Massachusetts, USA
    Cancer 118:2021-30. 2012
    ..Although breast cancer screening with mammography and magnetic resonance imaging (MRI) is recommended for breast cancer-susceptibility gene (BRCA) mutation carriers, there is no current consensus on the optimal screening regimen...
  6. ncbi VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:7871-7. 2008
    ....
  7. ncbi Which individuals undergoing BRACAnalysis need BART testing?
    Kristen M Shannon
    Massachusetts General Hospital, Center for Cancer Risk Assessment, Boston, MA, USA
    Cancer Genet 204:416-22. 2011
    ..These data suggest that when BRCA1 and BRCA2 genetic testing is performed, testing should always include LGR testing so that the results are the most comprehensive and reliable...
  8. ncbi Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8340-7. 2005
    ..The role of long-acting hematopoietic growth factors in facilitating every-2-week chemotherapy and minimizing hematologic toxicity has not been established...
  9. ncbi Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Breast Cancer Res 12:R95. 2010
    ....
  10. ncbi Professional challenges in cancer genetic testing: who is the patient?
    Gayun Chan-Smutko
    Massachusetts General Hospital Cancer Center Center for Cancer Risk Assessment, Boston, MA 02114, USA
    Oncologist 13:232-8. 2008
    ..In addition, post-test counseling should reiterate the implications of a positive result for at-risk relatives and conclude with a written summary that patients can share with their family...
  11. ncbi Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
    ..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
  12. ncbi Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort
    Ben S Wittner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 14:2988-93. 2008
    ..A molecular diagnostic test with high negative predictive value (NPV) for distant metastasis in this subgroup would spare many older breast cancer patients adjuvant treatment...
  13. ncbi Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis
    Janie M Lee
    Department of Radiology, Institute for Technology Assessment, Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 246:763-71. 2008
    ..To project intermediate and long-term clinical outcomes of magnetic resonance (MR) imaging screening for breast cancer in women with BRCA1 gene mutations...
  14. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer
    Paula D Ryan
    Gillette Center for Women's Cancer, Massachusetts General Hospital, Boston, USA
    N Engl J Med 349:1076-82. 2003
  15. ncbi Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
    Nadine Tung
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res 12:R12. 2010
    ..We undertook a study to assess the clinical factors that predict for an estrogen receptor positive (ER+) breast cancer in BRCA1 mutation carriers and to characterize the pathologic features of these tumors...
  16. ncbi Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:2889-95. 2003
    ..We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined with vinorelbine, and to assess cardiac surveillance algorithms and tumor markers as prognostic tools...
  17. ncbi Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer
    Paula D Ryan
    Department of Hematology, Massachusetts General Hospital, USA
    N Engl J Med 353:617-22. 2005
  18. ncbi Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations
    Kristen Mahoney Shannon
    Massachusetts General Hospital Cancer Center/Center for Cancer Risk Analysis, Boston, MA 02115, USA
    Genet Med 8:740-5. 2006
    ..CONCLUSION: Individuals who undergo genetic testing will not consistently pursue additional or enhanced genetic testing. Future research is needed to clearly elucidate the factors associated with uptake of additional genetic testing...
  19. ncbi Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder
    Paula D Ryan
    Department of Medical Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 354:850-6. 2006
  20. ncbi RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
    Dennis C Sgroi
    Cancer Cell 6:445. 2004
  21. ncbi A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
    Xiao-Jun Ma
    Arcturus Bioscience, Inc, 2715 Loker Avenue West, Carlsbad, CA 92008, USA
    Cancer Cell 5:607-16. 2004
    ..The HOXB13:IL17BR expression ratio may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer...
  22. ncbi Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
    Lyndsay N Harris
    Dana Farber Cancer Institute
    Clin Cancer Res 13:1198-207. 2007
    ....